Endocrine side effects during cancer treatment. Lecture for practitioners
- Authors: Glibka A.A.1, Mazurina N.V.1, Troshina E.A.1
 - 
							Affiliations: 
							
- Endocrinology Research Centre
 
 - Issue: Vol 24, No 6 (2022)
 - Pages: 416-421
 - Section: Articles
 - URL: https://bakhtiniada.ru/2075-1753/article/view/109885
 - DOI: https://doi.org/10.26442/20751753.2022.6.201695
 - ID: 109885
 
Cite item
Full Text
Abstract
Targeted therapy and immune checkpoint inhibitors (ICI) are increasingly being used to treat many solid tumors. The use alpelisib and ICPI has a risk of side-effects, particularly endocrine dysfunctions. In this lecture, there are clearly stated: initial screening, monitoring, selection of therapy and emergency situations for each endocrinopathy, i.e. hyperglycemia during treatment with alpelisib and destructive thyroiditis and hypophysitis during treatment of ICI.
Full Text
##article.viewOnOriginalSite##About the authors
Anastasiya A. Glibka
Endocrinology Research Centre
														Email: troshina@inbox.ru
				                	ORCID iD: 0000-0002-7324-8344
				                																			                								
Graduate Student
Russian Federation, MoscowNatalya V. Mazurina
Endocrinology Research Centre
														Email: natalyamazurina@mail.ru
				                	ORCID iD: 0000-0001-8077-9381
				                	SPIN-code: 9067-3062
																		                								
Cand. Sci. (Med.)
Russian Federation, MoscowEkaterina A. Troshina
Endocrinology Research Centre
							Author for correspondence.
							Email: troshina@inbox.ru
				                	ORCID iD: 0000-0002-8520-8702
				                																			                								
D. Sci. (Med.), Prof., Acad. RAS
Russian Federation, MoscowReferences
Supplementary files
				
			
					
						
				



